Adage Capital Partners Gp, L.L.C. Chemo Centryx, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$54.6 Billion
Q3 2024

Shares

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2020 Aug 14, 2020	SELL	$38.58 - $65.07 $13.5 Million - $22.8 Million	-350,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$32.73 - $50.78 $1.64 Million - $2.54 Million	50,000 Added 16.67%	350,000 $14.1 Million
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $2.04 Million - $11.9 Million	300,000 New	300,000 $11.9 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.